Quadrant Capital Group LLC Adaptive Biotechnologies Corp Transaction History

Quadrant Capital Group LLC

$1.42 Billion
Q3 2024

A detailed history of Quadrant Capital Group LLC transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Quadrant Capital Group LLC holds 8,876 shares of ADPT stock, worth $56,717. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,876

Previous 8,876 -0.0%

Holding current value

$56,717

Previous $32,000 40.63%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$2.34 - $3.96 $19,391 - $32,816	8,287 Added 1406.96%	8,876 $32,000
Q1 2024 May 15, 2024	BUY	$2.88 - $4.8 $1,696 - $2,827	589 New	589 $1,000
Q3 2023 Nov 14, 2023	SELL	$5.07 - $8.44 $5,526 - $9,199	-1,090 Reduced 89.71%	125 $0
Q2 2023 Aug 09, 2023	SELL	$6.19 - $8.78 $2,123 - $3,011	-343 Reduced 22.02%	1,215 $8,000
Q1 2023 May 11, 2023	BUY	$7.8 - $10.11 $1,497 - $1,941	192 Added 14.06%	1,558 $13,000
Q4 2022 Feb 10, 2023	BUY	$6.26 - $9.34 $1,258 - $1,877	201 Added 17.25%	1,366 $10,000
Q3 2022 Nov 10, 2022	SELL	$6.5 - $12.67 $247 - $481	-38 Reduced 3.16%	1,165 $8,000
Q2 2022 Aug 09, 2022	BUY	$6.4 - $14.73 $2,764 - $6,363	432 Added 56.03%	1,203 $10,000
Q1 2022 May 06, 2022	BUY	$10.12 - $28.9 $7,802 - $22,281	771 New	771 $10,000
Q4 2021 Feb 01, 2022	SELL	$25.17 - $36.85 $176 - $257	-7 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$30.02 - $39.87 $210 - $279	7 New	7 $0
Q2 2021 Aug 09, 2021	SELL	$32.22 - $44.59 $161 - $222	-5 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$37.26 - $67.74 $74 - $135	2 Added 66.67%	5 $0
Q4 2020 Feb 16, 2021	BUY	$45.01 - $65.47 $135 - $196	3 New	3 $0

Others Institutions Holding ADPT

# of Institutions

202

Shares Held

146M

Call Options Held

68.8K

Put Options Held

42.5K

View Full List

About Adaptive Biotechnologies Corp

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $913M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

More about ADPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.

Account

Quadrant Capital Group LLC Adaptive Biotechnologies Corp Transaction History